Pliant Therapeutics Receives FDA Orphan Drug Designation for Lead Program PLN-74809 in Primary Sclerosing Cholangitis

November 20, 2018

SOUTH SAN FRANCISCO, Calif., Nov. 20, 2018 /PRNewswire/ — Pliant Therapeutics, Inc., a biotechnology company focused on discovering, developing and commercializing treatments for fibrotic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the company’s anti-fibrotic lead compound, PLN-74809, for the treatment of primary sclerosing cholangitis (PSC). In addition, Bertus Eksteen, Ph.D., MBChB, FRCP, a leading clinical researcher in PSC, has joined Pliant’s scientific advisory board.

Full press release here.